newsfilter
← Latest News
Business Wire·

ImmunoCellular Therapeutics Appoints Andrew Gengos as Chief Executive Officer

LOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT: IMUC) announced today the appointment of Andrew Gengos as President and Chief Executive Officer and member of the Board of Directors. With more than 20 years in the life science industry, Mr. Gengos’ experience includes executive leadership positions in both large and emerging companies, with broad expertise in corporate strategy, business development and transactions, including mergers and acquisitions, financing, operations, commercial planning and healthcare policy.